Top-line data from Provectus' PH-10 Phase 2 trial on plaque psoriasis
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced top-line data for the company's randomized controlled trial (RCT) of PH-10 for mild-to-moderate plaque psoriasis.